Opinion by letter No  21 - The reimbursement of additional IVF cycles in the context of PGT‑M

Opinion by letter No 21 of 12 March 2026 on the reimbursement of additional IVF cycles in the context of PGT‑M

This opinion by letter addresses the question of whether it is appropriate to reimburse additional in vitro fertilisation (IVF) cycles when couples who are carriers of a hereditary genetic disorder use pre‑implantation genetic testing (PGT‑M) in order to avoid transmitting this condition to their future child. In Belgium, reimbursement is currently limited to six IVF cycles, regardless of the reason for the treatment. The Committee examines whether this rule leads, in the context of PGT‑M, to an equitable situation, given that certain embryos cannot be transferred because of an identified genetic risk. The opinion analyses this issue in the light of available scientific data and ethical considerations, in particular with regard to equality between patients, equity of outcomes, social justice and the responsible use of healthcare resources. It also highlights the possible alternatives that these couples may be confronted with. The Committee does not take a decision on reimbursement, but sets out the ethical issues that are relevant for political decision‑making bodies.

Opinion No 49 - PGD for healthy carriers of a severe hereditary disease 

Opinion No 49 of 20 April 2009 on the use of preimplantation genetic diagnosis (PGD) to detect healthy carriers of a mutation causing a severe hereditary disease for which offspring can have an increased risk 

Opinion No 3 - Sex selection 

Opinion No 3 of 17 November 1997 on Belgian Advisory Committee on Bioethics on sex selection